CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”)  (3696.HK),  a clinical-stage biotechnology company powered by generative artificialCAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”)  (3696.HK),  a clinical-stage biotechnology company powered by generative artificial

Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology

2026/02/06 21:31
5 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”)  (3696.HK),  a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology. Dr. Zhang will report to Feng Ren, Co-Chief Executive Officer and Chief Scientific Officer of Insilico Medicine, and will be based in the company’s Cambridge, Massachusetts office.

In this role, Dr. Zhang will lead the global clinical development strategy and execution for Insilico’s oncology portfolio, guiding both early- and late-stage programs across multiple tumor types. She will also contribute to broader portfolio planning and the company’s growth strategy, partnering closely with discovery, translational, biomarker, regulatory, and clinical operations teams to accelerate development timelines and deliver differentiated, patient-centered therapies.

Dr. Zhang is a strategic leader in oncology clinical development with more than 20 years of experience spanning academia, biotechnology, and the pharmaceutical industry. Most recently, she served as Global Clinical Development Program Leader for late-stage oncology and Global Program Leader for early oncology at Bristol Myers Squibb, where she was accountable for global development strategy and execution across multiple solid tumor indications, including lung, breast, melanoma, gastric, colorectal, bladder, and head and neck cancers. Her experience spans diverse therapeutic modalities, including immuno-oncology–based approaches, targeted small-molecule therapies, and antibody–drug conjugates (ADCs), leading programs from first-in-human studies through registrational trials.

She worked closely with global regulatory authorities to shape development strategies, optimize study design, and support regulatory submissions, while integrating translational science and biomarker strategies into clinical plans. Over the course of her career, she has built and scaled high-performing clinical development organizations and is recognized for fostering a culture of scientific rigor, accountability, and collaboration.

Earlier, Dr. Zhang held senior clinical development leadership roles at Infinity Pharmaceuticals and BioMed Valley Discoveries and began her career in academic research and clinical operations at Harvard Medical School, where she led NIH-sponsored clinical trials. She holds a PhD in Medicine and an MSc in Immunology and Microbiology from University of Birmingham, and a BSc in Nursing from University of Portsmouth.

“Halle brings exceptional scientific depth, strategic judgment, and operational excellence to Insilico’s oncology programs,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “Her proven leadership across global oncology development will be instrumental as we continue to expand our AI-driven pipeline and translate innovative science into meaningful clinical outcomes for patients.”

“I am excited to join Insilico Medicine at such an important stage of growth,” said Dr. Zhang. “Insilico’s unique AI-driven platform, combined with a bold, science-first culture, creates a powerful opportunity to rethink how oncology medicines are discovered and developed. I look forward to partnering with this talented team to advance therapies that address significant unmet needs for patients.”

Over the past year, Insilico Medicine’s oncology pipelines have been moving forward with high efficiency. Several innovative pipelines designed and optimized with the help of Chemistry42 have progressed to Phase I clinical trials. In January 2025, ISM6331, a pan-TEAD inhibitor with an innovative structure, was announced to have completed first patient dosing in a global, multicenter Phase I clinical trial for the treatment of mesothelioma and other solid tumors. In June 2025, ISM3412, a potential “best-in-class” inhibitor targeting MAT2A, was announced to have completed first patient dosing in patients with locally advanced and metastatic solid tumors, aiming to evaluate safety, tolerability, PK/PD characteristics, and preliminary efficacy.

In addition to advancing its internal pipeline, Insilico Medicine and its global partners have achieved multiple milestones across collaborative oncology programs. The company entered a multi-program discovery and development collaboration with Servier valued at up to USD $888 million to leverage Insilico’s AI platform to generate first-in-class small-molecule cancer therapies. Under its collaboration totaling up to USD $550 million with Menarini Group, Insilico received a USD $3 million development and regulatory milestone payment in July 2025, followed by a USD $5 million milestone upon dosing the first patient in the Phase I clinical trial of MEN2501 (ISM9682), a highly differentiated KIF18A small-molecule inhibitor.

Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development. While traditional early-stage drug discovery typically requires 3 to 6 years, from 2021 to 2024 Insilico nominated 20 preclinical candidates, achieving an average turnaround – from project initiation to preclinical candidate (PCC) nomination – of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.

About Insilico Medicine

Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.

Cision View original content:https://www.prnewswire.com/news-releases/insilico-medicine-appoints-halle-zhang-phd-med-as-vice-president-clinical-development–oncology-302681141.html

SOURCE Insilico Medicine

Market Opportunity
MASS Logo
MASS Price(MASS)
$0.0006508
$0.0006508$0.0006508
-0.39%
USD
MASS (MASS) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Unprecedented Surge: Gold Price Hits Astounding New Record High

Unprecedented Surge: Gold Price Hits Astounding New Record High

BitcoinWorld Unprecedented Surge: Gold Price Hits Astounding New Record High While the world often buzzes with the latest movements in Bitcoin and altcoins, a traditional asset has quietly but powerfully commanded attention: gold. This week, the gold price has once again made headlines, touching an astounding new record high of $3,704 per ounce. This significant milestone reminds investors, both traditional and those deep in the crypto space, of gold’s enduring appeal as a store of value and a hedge against uncertainty. What’s Driving the Record Gold Price Surge? The recent ascent of the gold price to unprecedented levels is not a random event. Several powerful macroeconomic forces are converging, creating a perfect storm for the precious metal. Geopolitical Tensions: Escalating conflicts and global instability often drive investors towards safe-haven assets. Gold, with its long history of retaining value during crises, becomes a preferred choice. Inflation Concerns: Persistent inflation in major economies erodes the purchasing power of fiat currencies. Consequently, investors seek assets like gold that historically maintain their value against rising prices. Central Bank Policies: Many central banks globally are accumulating gold at a significant pace. This institutional demand provides a strong underlying support for the gold price. Furthermore, expectations around interest rate cuts in the future also make non-yielding assets like gold more attractive. These factors collectively paint a picture of a cautious market, where investors are looking for stability amidst a turbulent economic landscape. Understanding Gold’s Appeal in Today’s Market For centuries, gold has held a unique position in the financial world. Its latest record-breaking performance reinforces its status as a critical component of a diversified portfolio. Gold offers a tangible asset that is not subject to the same digital vulnerabilities or regulatory shifts that can impact cryptocurrencies. While digital assets offer exciting growth potential, gold provides a foundational stability that appeals to a broad spectrum of investors. Moreover, the finite supply of gold, much like Bitcoin’s capped supply, contributes to its perceived value. The current market environment, characterized by economic uncertainty and fluctuating currency values, only amplifies gold’s intrinsic benefits. It serves as a reliable hedge when other asset classes, including stocks and sometimes even crypto, face downward pressure. How Does This Record Gold Price Impact Investors? A soaring gold price naturally raises questions for investors. For those who already hold gold, this represents a significant validation of their investment strategy. For others, it might spark renewed interest in this ancient asset. Benefits for Investors: Portfolio Diversification: Gold often moves independently of other asset classes, offering crucial diversification benefits. Wealth Preservation: It acts as a robust store of value, protecting wealth against inflation and economic downturns. Liquidity: Gold markets are highly liquid, allowing for relatively easy buying and selling. Challenges and Considerations: Opportunity Cost: Investing in gold means capital is not allocated to potentially higher-growth assets like equities or certain cryptocurrencies. Volatility: While often seen as stable, gold prices can still experience significant fluctuations, as evidenced by its rapid ascent. Considering the current financial climate, understanding gold’s role can help refine your overall investment approach. Looking Ahead: The Future of the Gold Price What does the future hold for the gold price? While no one can predict market movements with absolute certainty, current trends and expert analyses offer some insights. Continued geopolitical instability and persistent inflationary pressures could sustain demand for gold. Furthermore, if global central banks continue their gold acquisition spree, this could provide a floor for prices. However, a significant easing of inflation or a de-escalation of global conflicts might reduce some of the immediate upward pressure. Investors should remain vigilant, observing global economic indicators and geopolitical developments closely. The ongoing dialogue between traditional finance and the emerging digital asset space also plays a role. As more investors become comfortable with both gold and cryptocurrencies, a nuanced understanding of how these assets complement each other will be crucial for navigating future market cycles. The recent surge in the gold price to a new record high of $3,704 per ounce underscores its enduring significance in the global financial landscape. It serves as a powerful reminder of gold’s role as a safe haven asset, a hedge against inflation, and a vital component for portfolio diversification. While digital assets continue to innovate and capture headlines, gold’s consistent performance during times of uncertainty highlights its timeless value. Whether you are a seasoned investor or new to the market, understanding the drivers behind gold’s ascent is crucial for making informed financial decisions in an ever-evolving world. Frequently Asked Questions (FAQs) Q1: What does a record-high gold price signify for the broader economy? A record-high gold price often indicates underlying economic uncertainty, inflation concerns, and geopolitical instability. Investors tend to flock to gold as a safe haven when they lose confidence in traditional currencies or other asset classes. Q2: How does gold compare to cryptocurrencies as a safe-haven asset? Both gold and some cryptocurrencies (like Bitcoin) are often considered safe havens. Gold has a centuries-long history of retaining value during crises, offering tangibility. Cryptocurrencies, while newer, offer decentralization and can be less susceptible to traditional financial system failures, but they also carry higher volatility and regulatory risks. Q3: Should I invest in gold now that its price is at a record high? Investing at a record high requires careful consideration. While the price might continue to climb due to ongoing market conditions, there’s also a risk of a correction. It’s crucial to assess your personal financial goals, risk tolerance, and consider diversifying your portfolio rather than putting all your capital into a single asset. Q4: What are the main factors that influence the gold price? The gold price is primarily influenced by global economic uncertainty, inflation rates, interest rate policies by central banks, the strength of the U.S. dollar, and geopolitical tensions. Demand from jewelers and industrial uses also play a role, but investment and central bank demand are often the biggest drivers. Q5: Is gold still a good hedge against inflation? Historically, gold has proven to be an effective hedge against inflation. When the purchasing power of fiat currencies declines, gold tends to hold its value or even increase, making it an attractive asset for preserving wealth during inflationary periods. To learn more about the latest crypto market trends, explore our article on key developments shaping Bitcoin’s price action. This post Unprecedented Surge: Gold Price Hits Astounding New Record High first appeared on BitcoinWorld.
Share
Coinstats2025/09/18 02:30
Ripple pushes urgent XRPL patch — but nodes must trust its new key

Ripple pushes urgent XRPL patch — but nodes must trust its new key

The post Ripple pushes urgent XRPL patch — but nodes must trust its new key appeared on BitcoinEthereumNews.com. Ripple has released its fix for public-facing nodes
Share
BitcoinEthereumNews2026/03/14 03:04
Norwegian Krone hobbles ahead of uncertain Norges Bank decision

Norwegian Krone hobbles ahead of uncertain Norges Bank decision

The post Norwegian Krone hobbles ahead of uncertain Norges Bank decision appeared on BitcoinEthereumNews.com. The Norwegian Krone (NOK) remains in the spotlight ahead of the decisive Norges Bank interest rate decision scheduled for Thursday at 08:00 GMT. The EUR/NOK pair is trading around 11.60, up 0.3% on the day, after hitting 11.54 last week, its lowest level in three months. While the consensus is still for a 25 basis points rate cut to 4.00%, uncertainty remains high, fuelled by persistent core inflation at 3.1% and a solid economic outlook. This meeting, accompanied by the publication of the monetary policy report, could provoke a strong market reaction, as Norges Bank is renowned for its surprise decisions. A monetary dilemma for Norway Norway’s macroeconomic signals are confusing. On the one hand, inflation remains well above the central bank’s 2% target, with a technical adjustment that puts core inflation even closer to 3.5% than officially announced. “Altogether, today’s [inflation] figures were stronger than expected… This raises questions about whether Norges Bank will deliver a cut next week”, wrote Handelsbanken in a note relayed by Reuters, following the publication of Norway’s inflation data last week. The strength of the economy reinforces these doubts. Second-quarter Gross Domestic Product (GDP) grew by 0.6% against expectations of 0.3%, while the latest survey by Norges Bank’s regional network confirmed a stable growth outlook. “The central bank is not facing a continental economy in urgent need of easing,” observes Emil Lundh of MNI Markets, who favors a status quo by the central bank. However, other institutions still consider easing likely. ING believes that “despite sticky inflation and a solid outlook, we are still leaning towards a cut to 4.0%”, stresses FX strategist Francesco Pesole. TD Securities even speaks of a “hawkish cut”, underlining the likelihood of the decision being accompanied by a restrictive outlook to limit the impact on the NOK. The Oil…
Share
BitcoinEthereumNews2025/09/18 03:38